NR 567 / NR567 MIDTERM EXAM (2026/2027)
ADVANCED PHARMACOLOGY FOR THE
AGACNP QUESTIONS AND CORRECT
ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT
DOWNLOAD PDF
Core Domains:
• Pharmacokinetics and Pharmacodynamics
• Adrenergic and Cholinergic Pharmacology
• Cardiovascular Pharmacology (Antihypertensives,
Antiarrhythmics, Heart Failure)
• Central Nervous System Pharmacology (Antiepileptics,
Sedatives, Neuromuscular Blockers)
• Endocrine Pharmacology (Antidiabetics, Thyroid, Adrenal
Drugs)
• Antimicrobial Therapy and Stewardship
• Pain Management and Opioid Pharmacology
• Hematology and Coagulation (Anticoagulants, Antiplatelets)
• Critical Care Pharmacology (Vasopressors, Sedation,
Electrolyte Management)
• Special Populations (Geriatrics, Renal/Hepatic Impairment,
Pharmacogenomics)
Introduction
This comprehensive examination is designed for NR 567 Advanced
Pharmacology students preparing for their midterm assessment in
the Adult-Gerontology Acute Care Nurse Practitioner (AGACNP)
program at Chamberlain University. The exam evaluates mastery of
core pharmacological principles including pharmacokinetics,
pharmacodynamics, drug classifications, therapeutic decision-
making, and medication management in acute and critical care
settings. Through multiple-choice questions and clinical scenarios,
, students are challenged to integrate foundational pharmacology
with evidence-based prescribing practices, patient safety
considerations, and management of complex medication regimens
across diverse patient populations. Updated for the 2026/2027
academic year, this resource reflects current guidelines for sepsis,
heart failure, anticoagulation, and antimicrobial stewardship.
Successful completion demonstrates readiness for advanced
practice pharmacology competencies essential for the AGACNP role
.
SECTION ONE: QUESTIONS 1–100
Question 1
Which parameter primarily determines a drug's volume of distribution
(Vd)?
A. Renal clearance
B. Protein binding
C. Lipid solubility and tissue binding
D. Half-life
C. Lipid solubility and tissue binding
RATIONALE: Vd reflects how extensively a drug distributes into
tissues. Lipophilic drugs with high tissue binding have larger Vd,
indicating greater distribution out of the vascular compartment. Renal
clearance affects elimination, protein binding affects free drug
concentration, and half-life reflects elimination rate.
Question 2
A patient with severe hepatic failure will most likely have which change
in drug pharmacokinetics?
,A. Increased renal excretion
B. Decreased oral absorption
C. Reduced metabolism and prolonged half-life of hepatically cleared
drugs
D. Increased protein binding
C. Reduced metabolism and prolonged half-life of hepatically
cleared drugs
RATIONALE: Hepatic failure reduces metabolism of drugs cleared by
the liver (e.g., benzodiazepines, opioids, beta-blockers), increasing
half-life and exposure. Dose adjustments are required. Renal excretion
is not primarily affected, absorption changes are variable, and protein
binding typically decreases.
Question 3
A drug with a high first-pass effect is administered orally. Where is it
primarily metabolized before reaching systemic circulation?
A. Kidneys
B. Lungs
C. Liver
D. Stomach
C. Liver
RATIONALE: First-pass metabolism occurs in the liver. Kidneys
excrete drugs, lungs metabolize some drugs but not primary first-pass,
and stomach absorbs but does not significantly metabolize.
Question 4
A patient receives a drug with a half-life of 4 hours. Approximately how
many hours will it take to reach steady state?
, A. 8 hours
B. 12 hours
C. 20 hours
D. 40 hours
C. 20 hours
RATIONALE: Steady state is reached in 4-5 half-lives (20 hours for 5
half-lives). 8 hours is 2 half-lives, 12 hours is 3 half-lives, and 40 hours is
10 half-lives.
Question 5
A beta-1 selective antagonist is prescribed for a patient with
hypertension. Which effect is most expected?
A. Bronchospasm
B. Decreased heart rate
C. Peripheral vasodilation
D. Increased cardiac contractility
B. Decreased heart rate
RATIONALE: Beta-1 blockade decreases heart rate and contractility.
Bronchospasm results from beta-2 blockade, peripheral vasodilation
from alpha blockade, and increased contractility is the opposite effect.
Question 6
A patient taking warfarin has an INR of 4.5 without bleeding. Which
action is most appropriate?
A. Administer vitamin K
B. Hold the next dose and recheck INR
C. Increase the warfarin dose
D. Administer fresh frozen plasma
ADVANCED PHARMACOLOGY FOR THE
AGACNP QUESTIONS AND CORRECT
ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT
DOWNLOAD PDF
Core Domains:
• Pharmacokinetics and Pharmacodynamics
• Adrenergic and Cholinergic Pharmacology
• Cardiovascular Pharmacology (Antihypertensives,
Antiarrhythmics, Heart Failure)
• Central Nervous System Pharmacology (Antiepileptics,
Sedatives, Neuromuscular Blockers)
• Endocrine Pharmacology (Antidiabetics, Thyroid, Adrenal
Drugs)
• Antimicrobial Therapy and Stewardship
• Pain Management and Opioid Pharmacology
• Hematology and Coagulation (Anticoagulants, Antiplatelets)
• Critical Care Pharmacology (Vasopressors, Sedation,
Electrolyte Management)
• Special Populations (Geriatrics, Renal/Hepatic Impairment,
Pharmacogenomics)
Introduction
This comprehensive examination is designed for NR 567 Advanced
Pharmacology students preparing for their midterm assessment in
the Adult-Gerontology Acute Care Nurse Practitioner (AGACNP)
program at Chamberlain University. The exam evaluates mastery of
core pharmacological principles including pharmacokinetics,
pharmacodynamics, drug classifications, therapeutic decision-
making, and medication management in acute and critical care
settings. Through multiple-choice questions and clinical scenarios,
, students are challenged to integrate foundational pharmacology
with evidence-based prescribing practices, patient safety
considerations, and management of complex medication regimens
across diverse patient populations. Updated for the 2026/2027
academic year, this resource reflects current guidelines for sepsis,
heart failure, anticoagulation, and antimicrobial stewardship.
Successful completion demonstrates readiness for advanced
practice pharmacology competencies essential for the AGACNP role
.
SECTION ONE: QUESTIONS 1–100
Question 1
Which parameter primarily determines a drug's volume of distribution
(Vd)?
A. Renal clearance
B. Protein binding
C. Lipid solubility and tissue binding
D. Half-life
C. Lipid solubility and tissue binding
RATIONALE: Vd reflects how extensively a drug distributes into
tissues. Lipophilic drugs with high tissue binding have larger Vd,
indicating greater distribution out of the vascular compartment. Renal
clearance affects elimination, protein binding affects free drug
concentration, and half-life reflects elimination rate.
Question 2
A patient with severe hepatic failure will most likely have which change
in drug pharmacokinetics?
,A. Increased renal excretion
B. Decreased oral absorption
C. Reduced metabolism and prolonged half-life of hepatically cleared
drugs
D. Increased protein binding
C. Reduced metabolism and prolonged half-life of hepatically
cleared drugs
RATIONALE: Hepatic failure reduces metabolism of drugs cleared by
the liver (e.g., benzodiazepines, opioids, beta-blockers), increasing
half-life and exposure. Dose adjustments are required. Renal excretion
is not primarily affected, absorption changes are variable, and protein
binding typically decreases.
Question 3
A drug with a high first-pass effect is administered orally. Where is it
primarily metabolized before reaching systemic circulation?
A. Kidneys
B. Lungs
C. Liver
D. Stomach
C. Liver
RATIONALE: First-pass metabolism occurs in the liver. Kidneys
excrete drugs, lungs metabolize some drugs but not primary first-pass,
and stomach absorbs but does not significantly metabolize.
Question 4
A patient receives a drug with a half-life of 4 hours. Approximately how
many hours will it take to reach steady state?
, A. 8 hours
B. 12 hours
C. 20 hours
D. 40 hours
C. 20 hours
RATIONALE: Steady state is reached in 4-5 half-lives (20 hours for 5
half-lives). 8 hours is 2 half-lives, 12 hours is 3 half-lives, and 40 hours is
10 half-lives.
Question 5
A beta-1 selective antagonist is prescribed for a patient with
hypertension. Which effect is most expected?
A. Bronchospasm
B. Decreased heart rate
C. Peripheral vasodilation
D. Increased cardiac contractility
B. Decreased heart rate
RATIONALE: Beta-1 blockade decreases heart rate and contractility.
Bronchospasm results from beta-2 blockade, peripheral vasodilation
from alpha blockade, and increased contractility is the opposite effect.
Question 6
A patient taking warfarin has an INR of 4.5 without bleeding. Which
action is most appropriate?
A. Administer vitamin K
B. Hold the next dose and recheck INR
C. Increase the warfarin dose
D. Administer fresh frozen plasma
